The stock of Radius Health Inc (NASDAQ:RDUS) is a huge mover today! The stock decreased 2.01% or $1.11 during the last trading session, hitting $54.09. About 1.16 million shares traded hands or 10.48% up from the average. Radius Health Inc (NASDAQ:RDUS) has risen 84.61% since February 29, 2016 and is uptrending. It has outperformed by 74.18% the S&P500.
The move comes after 9 months negative chart setup for the $2.21B company. It was reported on Oct, 1 by Barchart.com. We have $50.30 PT which if reached, will make NASDAQ:RDUS worth $154.70M less.
Analysts await Radius Health Inc (NASDAQ:RDUS) to report earnings on November, 3. They expect $-1.04 earnings per share, down 52.94% or $0.36 from last year’s $-0.68 per share. After $-1.01 actual earnings per share reported by Radius Health Inc for the previous quarter, Wall Street now forecasts 2.97% negative EPS growth.
Radius Health Inc (NASDAQ:RDUS) Ratings Coverage
Out of 9 analysts covering Radius Health (NASDAQ:RDUS), 7 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 78% are positive. Radius Health has been the topic of 13 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The rating was downgraded by Jefferies on Wednesday, February 24 to “Hold”. On Friday, May 6 the stock rating was reinitiated by Cowen & Co with “Outperform”. The rating was maintained by Canaccord Genuity with “Buy” on Thursday, September 24. The firm has “Buy” rating given on Friday, August 14 by Deutsche Bank. JP Morgan initiated the stock with “Overweight” rating in Friday, October 2 report. The stock has “Buy” rating given by H.C. Wainwright on Wednesday, September 21. The firm earned “Neutral” rating on Wednesday, March 30 by Goldman Sachs. H.C. Wainwright initiated Radius Health Inc (NASDAQ:RDUS) on Monday, May 23 with “Buy” rating.
According to Zacks Investment Research, “Radius Health Inc. is a science-driven biopharmaceutical company. It is focused on developing novel differentiated therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. The Company’s lead product candidate, abaloparatide (BA058), is in development, in both injection (Abaloparatide-SC) and transdermal (Abaloparatide-TD) methods of administration, for the prevention of fractures in post-menopausal women at risk of fracture from osteoporosis. Radius Health Inc. is based in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment increased to 1.32 in Q2 2016. Its up 0.03, from 1.29 in 2016Q1. The ratio is positive, as 20 funds sold all Radius Health Inc shares owned while 33 reduced positions. 22 funds bought stakes while 48 increased positions. They now own 42.68 million shares or 5.94% more from 40.29 million shares in 2016Q1.
Farallon Management Limited Liability Com, a California-based fund reported 1.54M shares. Jefferies Group Limited Com has 2,140 shares for 0% of their US portfolio. Blackrock Incorporated holds 0% or 2,852 shares in its portfolio. Alps Advsr Incorporated has 60,460 shares for 0.02% of their US portfolio. Credit Suisse Ag owns 129,251 shares or 0.01% of their US portfolio. Blackrock Fund Advsrs last reported 0.01% of its portfolio in the stock. Metropolitan Life Ins Communications Ny, a New York-based fund reported 23,097 shares. State Board Of Administration Of Florida Retirement Sys has 0% invested in the company for 21,248 shares. The Colorado-based Centurylink has invested 0.08% in Radius Health Inc (NASDAQ:RDUS). New York State Common Retirement Fund holds 92,673 shares or 0% of its portfolio. The Florida-based Carl Domino Inc has invested 0.19% in Radius Health Inc (NASDAQ:RDUS). Geode Limited Liability Company last reported 241,121 shares in the company. Dafna Capital Mngmt Ltd Com has 1.1% invested in the company for 37,600 shares. Artal Grp owns 100,000 shares or 0.08% of their US portfolio. Alliancebernstein Ltd Partnership reported 430,600 shares or 0.01% of all its holdings.
Another recent and important Radius Health Inc (NASDAQ:RDUS) news was published by Streetinsider.com which published an article titled: “Form 4 Radius Health, Inc. For: Sep 27 Filed by: EVNIN LUKE” on September 29, 2016.
RDUS Company Profile
Radius Health, Inc. is a biopharmaceutical firm focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. The Company’s clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. The Company’s preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for use in cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.